Nureca

Which are the latest news on Nureca?

Why is Nureca Ltd falling/rising?

As of 05-Sep, Nureca Ltd's stock price is declining, currently at 325.00, down 2.69%. The stock has underperformed the market and shows signs of short-term weakness, with significant drops in delivery volume and sector performance.

As of 05-Sep, Nureca Ltd's stock price is falling, currently at 325.00, which reflects a decrease of 9.0 points or 2.69%. This decline is evident in the stock's performance today, where it touched an intraday low of Rs 320.85, representing a drop of 3.94%. The stock has also underperformed compared to the broader market, with a 1-week return of -1.92% compared to the Sensex's -0.97%. <BR><BR>Additionally, the sector in which Nureca operates, Medical Equipment/Supplies/Accessories, has seen a significant decline of 3.52%. Investor participation appears to be waning, as indicated by a 65.36% drop in delivery volume on September 3rd compared to the 5-day average. Although the stock is trading above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, suggesting a short-term weakness. Overall, these factors contribute to the downward pressure on Nureca Ltd's stock price.

Who are in the management team of Nureca?

The management team of Nureca includes Saurabh Goyal (Chairman & Managing Director), Aryan Goyal (Whole Time Director & CEO), and several Independent Directors: Vijay Kumar Sharma, Charu Singh, Ruchita Agarwal, and Vikram Chaudhary, along with Chetna Anand (Company Secretary & Compliance Officer). This diverse team contributes to the company's strategic direction and governance.

The management team of Nureca includes the following individuals:<BR><BR>1. **Saurabh Goyal** - Chairman & Managing Director<BR>2. **Vijay Kumar Sharma** - Independent Director<BR>3. **Charu Singh** - Independent Director<BR>4. **Ruchita Agarwal** - Independent Director<BR>5. **Vikram Chaudhary** - Independent Director<BR>6. **Chetna Anand** - Company Secretary & Compliance Officer<BR>7. **Aryan Goyal** - Whole Time Director & CEO<BR><BR>This team brings a diverse range of expertise to the company, contributing to its strategic direction and governance.

What does Nureca do?

Nureca Ltd is a digitally native consumer healthcare company in India, categorized as a Micro Cap, with net sales of 40 Cr and a net profit of 3 Cr for June 2026. It was incorporated in 2016 and became a public company in 2020.

Overview:<BR>Nureca Ltd is a digitally native consumer healthcare company operating in the Healthcare Services industry, categorized as a Micro Cap.<BR><BR>History:<BR>Nureca Limited was incorporated as Nureca Private Limited in India on 02 November 2016. It converted to a Public Limited Company on 08 July 2020, at which point its name was changed to Nureca Limited. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 40 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 3 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 307 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 74.00 <BR>Industry P/E: 112 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.22 <BR>Return on Equity: 1.15% <BR>Price to Book: 1.77 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Nureca?

Nureca's peers include Health X Platfor, Hemant Surgical, Prevest Denpro, Take, Bilcare, and QMS Medical. Nureca has the highest 1-year return at 41.92%, while Prevest Denpro has the lowest at -32.25%.

Peers: The peers of Nureca are Health X Platfor, Hemant Surgical, Prevest Denpro, Take, Bilcare, and QMS Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Health X Platfor and Prevest Denpro, while Average management risk is found at Hemant Surgical and QMS Medical, and Below Average management risk is noted at Nureca, Take, and Bilcare. Good growth is seen at Hemant Surgical and Bilcare, while Below Average growth is present at Health X Platfor, Prevest Denpro, Nureca, Take, and QMS Medical. Excellent capital structure is attributed to Health X Platfor and Prevest Denpro, Good capital structure is noted at Nureca and Average capital structure is found at QMS Medical, while Below Average capital structure is observed at Take and Bilcare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Nureca at 41.92%, while the lowest is Prevest Denpro at -32.25%. Nureca's 1-year return is significantly higher than its peers. Additionally, the six-month return is negative for Prevest Denpro, Take, and QMS Medical.

How big is Nureca?

As of 31st August, Nureca Ltd has a market capitalization of 307.00 Cr, with net sales of 153.13 Cr and a net profit of 4.34 Cr over the latest four quarters. Shareholder's funds were 180.76 Cr and total assets were 193.62 Cr as of March 2026.

As of 31st August, Nureca Ltd has a market capitalization of 307.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Nureca reported net sales of 153.13 Cr and a net profit of 4.34 Cr.<BR><BR>For the latest annual period ending in March 2026, Nureca's shareholder's funds amounted to 180.76 Cr, while total assets were reported at 193.62 Cr.

Should I buy, sell or hold Nureca Ltd?

Are Nureca Ltd latest results good or bad?

Nureca Ltd's latest results show strong revenue growth, achieving ₹40.34 crores with an 18.02% year-on-year increase, but profitability concerns arise due to reliance on non-operating income and a fragile operating margin of 8.48%. While there are positive trends, investors should be cautious about the sustainability of earnings.

Nureca Ltd's latest results present a mixed picture. On one hand, the company achieved its highest quarterly revenue in recent history at ₹40.34 crores, marking an impressive 18.02% year-on-year growth and a 13.92% sequential increase. This indicates strong top-line momentum and suggests that management's turnaround efforts are starting to bear fruit after a challenging previous fiscal year.<BR><BR>However, the profitability aspect raises concerns. While the net profit of ₹3.07 crores reflects a remarkable 279.01% increase year-on-year, this figure is somewhat misleading due to the low base from the previous year. Furthermore, a significant portion of the profit before tax—41.08%—came from other income, which raises questions about the sustainability of the company's core earnings. The operating margin improved to 8.48%, a notable recovery from a loss the previous year, yet it still highlights the fragility of the company's profitability.<BR><BR>Overall, while the quarterly performance shows positive trends in revenue and margin recovery, the heavy reliance on non-operating income and the underlying challenges in generating robust operational cash flows suggest that the results are not entirely positive. Investors should approach with caution, considering both the encouraging growth and the structural weaknesses that remain.

When is the next results date for Nureca Ltd?

The next results date for Nureca Ltd is July 21, 2026.

The next results date for Nureca Ltd is scheduled for July 21, 2026.

How has been the historical performance of Nureca?

Nureca's historical performance has shown significant declines in net sales, operating profit, and profitability, with net sales dropping from 255.55 Cr in Mar'22 to 109.66 Cr in Mar'25, and operating profit turning negative by Mar'25. Despite slight increases in total assets and liabilities, the company has faced challenging financial conditions with negative cash flow from operating activities.

Answer:<BR>The historical performance of Nureca shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Nureca's net sales have varied considerably, peaking at 255.55 Cr in Mar'22 before declining to 109.66 Cr in Mar'25. The total operating income followed a similar trend, with a high of 255.55 Cr in Mar'22 and dropping to 109.66 Cr in Mar'25. The company's total expenditure, excluding depreciation, has also seen fluctuations, reaching a high of 200.04 Cr in Mar'22 and decreasing to 117.20 Cr in Mar'25. Operating profit, which was 63.21 Cr in Mar'22, turned negative in subsequent years, culminating in a loss of 7.54 Cr in Mar'25. Profit before tax showed a similar decline, moving from 60.98 Cr in Mar'22 to a modest profit of 1.34 Cr in Mar'25. The profit after tax also reflected this trend, with a significant drop from 44.96 Cr in Mar'22 to 0.85 Cr in Mar'25. The company's total assets increased slightly from 200.26 Cr in Mar'24 to 206.50 Cr in Mar'25, while total liabilities also rose from 200.26 Cr to 206.50 Cr in the same period. Cash flow from operating activities has been negative in recent years, with a notable outflow of 19.00 Cr in Mar'25. Overall, Nureca's financial performance indicates a challenging period with declining revenues and profitability, despite some stability in asset and liability levels.

Who are the top shareholders of the Nureca?

The top shareholders of Nureca include promoter Saurabh Goyal with 31.86%, individual investors with 32.39%, and four Foreign Institutional Investors holding 1.07%. The highest public shareholder is Nisarg Vakharia at 1.78%, with no mutual funds currently invested.

The top shareholders of Nureca include the promoters, who hold a significant portion of the company's shares. The promoter with the highest holding is Saurabh Goyal, owning 31.86% of the shares. Additionally, individual investors collectively hold 32.39% of the shares. In terms of institutional investors, there are four Foreign Institutional Investors (FIIs) that hold a total of 1.07%. The highest public shareholder is Nisarg Vakharia, with a holding of 1.78%. There are no mutual funds currently holding shares in Nureca.

Is Nureca overvalued or undervalued?

As of November 14, 2022, Nureca is considered overvalued with a high PE ratio of 287.01 and negative EV to EBIT and EBITDA ratios, leading to a valuation grade shift from very attractive to risky, despite a recent stock return of 5.53%.

As of 14 November 2022, the valuation grade for Nureca has moved from very attractive to risky, indicating a significant shift in its financial outlook. The company is currently assessed as overvalued, primarily due to its exceptionally high PE ratio of 287.01 and negative EV to EBIT and EV to EBITDA ratios of -24.77 and -32.45, respectively. Additionally, the return on capital employed (ROCE) stands at -6.50%, further highlighting the challenges the company faces in generating returns.<BR><BR>In comparison to its peers, Nureca's valuation metrics are starkly higher; for instance, Poly Medicure Ltd. has a PE ratio of 66.7 and an EV to EBITDA of 47.56, while Vimta Labs Ltd. shows a PE of 34.32 and an EV to EBITDA of 18.35. These comparisons underscore Nureca's overvaluation relative to its industry. Despite a recent stock return of 5.53% over the past week, which outperformed the Sensex's 1.39%, the overall financial indicators suggest that Nureca's current market price of 283.50 is not justified by its underlying performance.

What is the technical trend for Nureca?

As of June 3, 2025, Nureca's technical trend is mildly bullish, supported by weekly MACD, KST, and Dow Theory indicators, despite some caution from daily moving averages and mixed signals from Bollinger Bands.

As of 3 June 2025, the technical trend for Nureca has changed from sideways to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, supporting the positive outlook. The Dow Theory also aligns with this stance, indicating a mildly bullish trend on both weekly and monthly time frames. However, the daily moving averages are mildly bearish, which introduces some caution. The Bollinger Bands show a bullish signal on the weekly but a mildly bearish signal on the monthly, adding to the mixed signals. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, KST, and Dow Theory indicators.

Has Nureca declared dividend?

Nureca Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of February 24, 2022. However, the dividend yield is currently 0%, and the company has shown significant negative total returns over various periods.

Nureca Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 24 Feb 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -1.71%, the dividend return was 0%, resulting in a total return of -1.71%.<BR><BR>Over the past year, the price return was 8.92%, the dividend return was 0%, leading to a total return of 8.92%.<BR><BR>For the 2-year period, the price return was -26.2%, with a dividend return of 0%, resulting in a total return of -26.2%.<BR><BR>In the 3-year period, the price return was -73.96%, the dividend return was 0%, culminating in a total return of -73.96%.<BR><BR>Over the last 4 years, the price return was -81.2%, with a dividend return of 0.31%, resulting in a total return of -80.89%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Nureca Ltd has declared a dividend, the dividend yield is currently 0%, indicating that the company has not consistently provided dividends in recent periods. The total returns over various periods show significant volatility, particularly with negative returns in the longer terms.